MPN

(redirected from Myeloproliferative Neoplasm)
Also found in: Wikipedia.
AcronymDefinition
MPNMaster Promissory Note
MPNMost Probable Number (microbiology method)
MPNMedical Provider Network
MPNMicrosoft Partner Network (business community)
MPNMobil Producing Nigeria
MPNMicrosoft Passport Network
MPNMulti Protocol Network
MPNMinority Professional Network (Atlanta, GA)
MPNMennonite Publishing Network
MPNManufacturer's Part Number
MPNMyeloproliferative Neoplasm
MPNMolex Premise Network (various locations)
MPNMilitary Personnel, Navy
MPNMaximum Possible Number (EPA)
MPNMore Productive Now! (blog)
MPNManaged Private Network
MPNMissouri Political News
MPNMode Partition Noise
MPNMSE Packet Network
MPNMobile Private Network
MPNMean Probable Number
MPNMilitary Pay, Navy
MPNMature Professionals Network
MPNModulatory Proctolin Neuron
MPNManagement Professional Network (IEEE)
MPNModular Personal Network (Celume)
MPNMission Packet-Switch Network
MPNMobility Position Number
MPNMessage Packet Network
MPNMcCulloch-Pitts Neural Model
MPNMessaging Pipeline Newsletter (web newsletter)
References in periodicals archive ?
Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms. Am J Clin Pathol 2015;144:188-206.
Role of Jak and STAT proteins with hematological neoplasms, alteration in Jak-Stat pathway confers the hematological as well as non hematological malignancies.3 The most common hematological malignancies include the myeloproliferative neoplasms (i.e.
Impact of inflammation on myeloproliferative neoplasm symyom development.
Myeloproliferative neoplasms can demonstrate overproduction of one or more of the formed elements from the bone marrow and are said to be able to mimic one another.
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients.
With the bone marrow picture, a myeloproliferative neoplasm was confirmed.
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia.
miR-28-5p target Tumor type Reference p21 Choriocarcinoma cells [15] MPL Myeloproliferative neoplasms [16] N4BP1 Myeloproliferative neoplasms/ [9] ovarian cancer OTUB1 Myeloproliferative neoplasms [16] TEX-261 Myeloproliferative neoplasms [16] MAPK1 Myeloproliferative neoplasms [16] E2F6 Myeloproliferative neoplasms [16] MAD2L1 B-cell lymphomas [5] BAG1 B-cell lymphomas [5] RAP1B B-cell lymphomas/renal cell [3, 5] carcinoma
Patients presenting with eosinophilia-associated myeloproliferative neoplasm who lack overexpression of PDGFRA or PDGFRB have been imatinib-responsive [6], emphasizing that it is reasonable to begin a therapeutic trial with tyrosine kinase inhibitors in symptomatic patients pending further gene fusion characterization.
Objective: To determine the frequency of Janus associated kinase 2 mutation in the patients of BCR-ABL negative classical myeloproliferative neoplasms.
Bone marrow assessment was performed to rule out a primary hematopoietic process; findings included slightly hypercellular marrow but with no evidence of a myeloproliferative neoplasm. Molecular studies were negative for BCR-ABL gene transcripts (associated with chronic myelogenous) and for the variant JAK2 allele (associated with polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis).
Myelofibrosis is classified as a myeloproliferative neoplasm, a group of rare blood cancers that derive from blood-forming stem cells.